Read by QxMD icon Read

Journal of Dermatological Treatment

T Gupta, K Sardana, B Kumar, H K Gautam
No abstract text is available yet for this article.
May 26, 2017: Journal of Dermatological Treatment
Hans Stettler, Peter Kurka, Johannes Kandzora, Viktoria Pavel, Marion Breuer, Anna Macura-Biegun
PURPOSE: A study was conducted with a new topical panthenol-containing emollient (NTP-CE) to investigate the efficacy and safety of a 3-month maintenance treatment in infants and children with stabilized mild atopic dermatitis (AD). METHODS: After the stabilization phase (up to 2 months) using a corticosteroid-free topical medical device, 108 subjects (aged 2-49 months) with a SCORing AD (SCORAD) on the target area of <5, were randomized to receive NTP-CE (N = 52) or reference emollient (N = 56) twice-daily for ∼3 months...
May 24, 2017: Journal of Dermatological Treatment
Alicia D Bucko, Michael Jarratt, Dowling B Stough, Laerke Kyhl, John Villumsen, Anders Hall
PURPOSE: Actinic keratoses (AKs) exist on a continuum with squamous cell carcinoma and can occur as sub-clinical and clinically visible lesions in cancerized fields on sun-damaged skin. Ingenol mebutate effectively treats AKs on areas up to 25 cm(2), but actinic keratosis can affect larger areas of skin. This trial evaluated systemic exposure and safety of ingenol mebutate gel on larger areas of skin under maximum use conditions. METHODS: Phase I, multicenter, open-label, uncontrolled, non-randomized trial...
May 19, 2017: Journal of Dermatological Treatment
F Dragoni, S Moretti, G Cannarozzo, P Campolmi
Purpose Surgical treatment remains the first-line therapy of pilonidal cyst but is associated with high levels of post-operative pain, adverse events and a recurrence rate of 30%. We report our experience with laser hair removal using the Nd-YAG laser for the treatment of pilonidal cyst. Materials and methods Ten patients affected by pilonidal cyst were examined and treated from October 2011 to November 2016. Treatments were carried out using the Nd-YAG laser (Deka M.E.L.A, Calenzano, Florence, Italy) at a wavelength of 1064 nm at 30-day intervals...
May 18, 2017: Journal of Dermatological Treatment
Megan Hohenberger, Leah A Cardwell, Elias Oussedik, Steven R Feldman
INTRODUCTION: Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exacerbations of inflammatory bowel disease have been reported in anti-IL-17 psoriasis trials. AIM: To characterize the relationship between IL-17 inhibition and inflammatory bowel disease. METHODS: A review of English-language articles was performed. Search terms included IL-17, psoriasis, inflammatory bowel disease, secukinumab, ixekizumab, and brodalumab...
May 18, 2017: Journal of Dermatological Treatment
Amal Ahmad El-Ashmawy, Iman Hamed El-Maadawy, Gamal Mohamed El-Maghraby
BACKGROUND: Alopecia areata (AA) is one of the most common causes of localized hair loss. There is no universally proven therapy that induces and sustains remission of hair growth in AA. OBJECTIVE: To compare the efficacy and safety of topical latanoprost, minoxidil and betamethasone valerate on hair growth in patients with AA. PATIENTS AND METHODS: 100 patients with AA classified into 5 groups of 20 treated with: I, latanoprost 0.1% lotion; II, minoxidil 5% lotion; III, betamethasone valerate 0...
May 18, 2017: Journal of Dermatological Treatment
Aditya K Gupta, Steve Hall, Lee T Zane, Shari R Lipner, Phoebe Rich
PURPOSE: The role of topical antifungal agents in the long-term management of toenail onychomycosis is not well established. The current study evaluated durability of clinical benefit of tavaborole topical solution, 5%, for the treatment of toenail onychomycosis. METHODS: We conducted a pooled analysis of 8-week, poststudy follow-up (PSFU) data from two phase 3, randomized controlled trials in a subset of patients who experienced complete or almost clear nail at the end of treatment (week 52); 48 weeks of treatment with once-daily tavaborole compared with placebo in adults with distal subungual onychomycosis was evaluated at week 60...
May 18, 2017: Journal of Dermatological Treatment
Jesper Grønlund Holm, Ilya Ivyanskiy, Simon Francis Thomsen
BACKGROUND: Knowledge of effectiveness and safety of the non-biologic, non-antihistamine treatments used for chronic urticaria is important as in some cases the principal guideline-recommended drug; omalizumab, has limited effect, side effects, or is too expensive or unavailable. Herein we systematically review the evidence for the use of the non-biologic treatments in antihistamine-refractory chronic urticaria. METHODS: We performed a systematic review of the literature using PubMed and Webofscience and identified studies that reported use of one or more of the non-biological, non-antihistamine treatment options for chronic urticaria...
May 17, 2017: Journal of Dermatological Treatment
Nemanja Damjanov, Sarolta Karpati, Lajos Kemeny, Noemi Bakos, Branislav Bobic, Maria Majdan, Witold Tlustochowicz, Petr Vitek, Eva Dokoupilova, Emre Aldinc, Annette Szumski
BACKGROUND: Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis (PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of etanercept (ETN) in PsA patients from CEE. METHODS: In PRESTA, patients were randomised to receive ETN 50 mg BIW or 50 mg QW for 12 weeks (double-blind phase), and ETN 50 mg QW for 12 additional weeks (open-label). In this analysis only patients from Czech Republic, Hungary, Poland, and Serbia were included...
May 16, 2017: Journal of Dermatological Treatment
Siin Kim, Hyung Tae Kim, Hae Sun Suh
BACKGROUND: Although BRAF inhibitors have been used to treat advanced melanoma with BRAF mutation, combination strategies are suggested due to acquired resistance to BRAF inhibitors. OBJECTIVE: To assess the efficacy of BRAF inhibitor-based combination therapy for the treatment of advanced melanoma with BRAF mutation. METHODS: We conducted a systematic review and meta-analysis of studies that compared BRAF inhibitor-based combination therapy with BRAF inhibitor monotherapy...
May 15, 2017: Journal of Dermatological Treatment
Ehrhardt Proksch, Raymond de Bony, Sonja Trapp, Stéphanie Boudon
Approximately 70 years ago, the first topical dexpanthenol-containing formulation (Bepanthen™ Ointment) has been developed. Nowadays, various topical dexpanthenol preparations exist, tailored according to individual requirements. Topical dexpanthenol has emerged as frequently used formulation in the field of dermatology and skin care. Various studies confirmed dexpanthenol's moisturizing and skin barrier enhancing potential. It prevents skin irritation, stimulates skin regeneration and promotes wound healing...
May 14, 2017: Journal of Dermatological Treatment
Mohammed D Saleem, Deborah Negus, Steven R Feldman
BACKGROUND: Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence, and efficacy. OBJECTIVE: To evaluate the efficacy of topical desoximetasone 0.25% spray formulation in extensive psoriasis. METHODS: This multicenter, double-blinded, randomized trial compared twice daily topical 0...
May 13, 2017: Journal of Dermatological Treatment
A Baran, H Myśliwiec, M Szterling-Jaworowska, P Kiluk, M Świderska, I Flisiak
OBJECTIVE: YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment. METHODS: A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled...
May 12, 2017: Journal of Dermatological Treatment
Angelyn O Fairchild, Shelby D Reed, F Reed Johnson, Greg Anglin, Anne M Wolka, Rebecca A Noel
PURPOSE: The purpose of this study was to provide quantitative evidence of patients' tolerance for therapeutic risks associated with psoriasis treatments that could offer psoriasis improvements beyond the PASI 75 benchmark. MATERIALS AND METHODS: We used a discrete-choice experiment in which respondents chose between competing psoriasis treatments characterized by benefits (ie, reduced plaque severity, reduced plaque area), risks (ie, 10-year risk of tuberculosis, 10-year risk of death from infection), and treatment regimen...
May 12, 2017: Journal of Dermatological Treatment
Mohammed D Saleem, Steven R Feldman
BACKGROUND: In extensive psoriasis, topical corticosteroids are generally only used to supplement phototherapy and systemic therapy. Spray formulations are easier than other vehicle preparations to apply and may be an option for treating extensive psoriasis. OBJECTIVE: To evaluate the potential for hypothalamic-pituitary-adrenal axis suppression and efficacy of topical desoximetasone 0.25% spray formulation in patients with extensive psoriasis. METHODS: A multicenter, open label, non-randomized, clinical trial was conducted...
May 12, 2017: Journal of Dermatological Treatment
Filip Rob, Jana Hercogová
OBJECTIVE: To evaluate effectivity, safety and patients' adherence to Benzathine Penicillin G (BPG) 1,200,000 units (1.2 MU) once-every-3-week intramuscularly prophylaxis for recurrent erysipelas. METHODS: Patients with documented two or more erysipelas episodes in last two years who received at least one of ten planned doses of BPG 1.2 MU intramuscularly between January 2009 and December 2015 were analyzed in this retrospective study. Number of recurrences during the 30-week prophylaxis and in the 30-week follow-up period, frequency of adverse events, patients' adherence to the treatment and factors associated with the recurrence were analyzed...
May 10, 2017: Journal of Dermatological Treatment
Ewa Chlebus, Marcin Chlebus
OBJECTIVE: To identify factors improving symptoms and shortening duration of AA. MATERIAL AND METHODS: The observational cohort study was performed in 111 patients with AA (> 25 y.o.) in 2015-2016. Clinical manifestation, previous treatments, environmental risk factors and features of juvenile acne affecting AA were assessed. RESULTS: The maximum severity of persistent acne was significantly lower after 25 years of age, as compared to adolescence (7...
May 10, 2017: Journal of Dermatological Treatment
Jinguang He, Tao Wang, Jiasheng Dong
PURPOSE: For patients with axillary bromhidrosis, it is not clear that whether a low response to initial Botulinum toxin A (BTX-A) treatment is related to poor long-term outcomes. PATIENTS AND METHODS: From August 2011 to March 2016, 31 patients with primary axillary bromhidrosis were recruited. They had the duration of efficacy for less than 4 weeks (median, 3 weeks; range, 1-3 weeks) after the first BTX-A injection (50U per underarm) and were considered to have a low response to BTX-A treatment...
May 10, 2017: Journal of Dermatological Treatment
Luis Daniel Mazzuoccolo, Paula Carolina Luna, Sebastián Marciano, Gimena Antonia Castro Perez, Carolina Marchesi, Mabel Jimena Nocito, Vanesa Martin Koller, Jimena Lorenzo, Claudia Koch, Cristina Mariela Echeverria
OBJECTIVE: to describe dermatologists´ methotrexate prescription trends for the treatment of psoriasis, and to identify variables associated with suboptimal methotrexate use. METHODS: Cross sectional study of dermatologists from Argentina who completed a pre-designed survey focused on methotrexate prescription characteristics. A multiple logistic regression model was used to identify variables independently associated with suboptimal methotrexate use (when less than 12 weeks and less than 15 mg/week were administrated in patients with monotherapy before discontinuing or adding a second drug) Results: 221 dermatologists participated in the study...
May 10, 2017: Journal of Dermatological Treatment
Diana Norris, Louise Photiou, Mark Tacey, Con Dolianitis, George Varigos, Peter Foley, Chris Baker
BACKGROUND/OBJECTIVES: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilises data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change. METHODS: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. All subjects from the registry that had DLQI and Psoriasis Assessment Severity Index (PASI) scores recorded at a baseline timepoint of treatment commencement, in addition to week 12 and 24 post commencement were included in the study...
May 10, 2017: Journal of Dermatological Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"